Anika Therapeutics (ANIK) Cash from Financing Activities (2010 - 2026)

Anika Therapeutics (ANIK) has reported Cash from Financing Activities for 17 consecutive years, with -$701000.0 the latest figure, recorded in Q2 2026.

• In Q2 2026, Cash from Financing Activities fell 491.62% year-over-year to -$701000.0; the TTM figure through Jun 2026 stood at -$16.3 million (down 11.89% YoY), while the FY2025 annual figure was -$10.6 million, up 17.11% from the prior year.
• Cash from Financing Activities grew to -$701000.0 in Q2 2026 per ANIK's latest filing, from -$10.3 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $667000.0 in Q4 2022 and bottomed at -$10.3 million in Q1 2026.
• Historically, Cash from Financing Activities has averaged -$2.5 million across 5 years, with a median of -$1.4 million in 2023.
• Annual changes were most pronounced in 2022 — Cash from Financing Activities soared 1011.67% — and 2023, when it plunged 10645.65%.
• Anika Therapeutics' Cash from Financing Activities stood at $667000.0 in 2022, then slumped by 48.73% to $342000.0 in 2023, then slumped by 1665.5% to -$5.4 million in 2024, then climbed by 1.4% to -$5.3 million in 2025, then surged by 86.72% to -$701000.0 in 2026.
• Business Quant data shows ANIK's Cash from Financing Activities at -$701000.0 in Q2 2026, -$10.3 million in Q1 2026, and -$5.3 million in Q4 2025.